Stefanos Theoharis
Chief Executive Officer OneChain Immunotherapeutics
Stefanos has over 20 years of broad experience in the cell and gene therapy space, business development, program management, manufacturing and basic research, and a deep knowledge C> sector. He is the former CBO of Bone Therapeutics, a Belgium-based company developing specialized cell therapies for orthopaedic disorders. Pior to that he was SVP at Cell Medica, and CBO at apceth GmbH. He also held positions as Head of Business Development at the antisense RNA drug specialist Antisense Pharma (now Isarna), and Director of Business Development at Roche, focused on partnering activities in emerging science and technologies. Stefanos also worked at Lazard, the global investment bank, advising to a variety of life sciences firms on M&As and financing transactions. He holds a PhD in gene therapy and immunology from Imperial College London.
Seminars
- Discussing the challenges in evaluating CAR-T cell therapies preclinically and the rationale to select relevant preclinical models
- Presenting lessons learned to tackle antigen expression and ensure the representation of the patient tumour microenvironment
- Leveraging model data to predict efficacy and safety of CAR-T therapies to ensure translation to the clinic
